Scarica l'app Stockscreener
63.99
4.73%
2.89
Dopo l'orario di chiusura:
64.36
0.37
+0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$61.10
Aprire:
$61.19
Volume 24 ore:
3.02M
Relative Volume:
1.19
Capitalizzazione di mercato:
$5.82B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-22.85
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-5.35%
1M Prestazione:
-1.27%
6M Prestazione:
+65.48%
1 anno Prestazione:
+37.94%
Intervallo 1D:
$60.53
$65.98
Intervallo di 1 settimana:
$60.53
$67.73
Portata 52W:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
63.99 | 5.56B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Why CRISPR Therapeutics AG (1CG) stock is listed among top recommendationsQuarterly Trade Report & Smart Swing Trading Techniques - newser.com
Why CRISPR Therapeutics AG stock could rally in 2025Weekly Trend Report & AI Powered Market Entry Strategies - newser.com
Will CRISPR Therapeutics AG (1CG) stock gain from green policies2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
What valuation multiples suggest for CRISPR Therapeutics AG stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsMarket Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
Y Intercept Hong Kong Ltd Makes New $1.91 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 6,003 CRISPR Therapeutics AG $CRSP - MarketBeat
Has CRISPR Therapeutics AG found a price floorJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
How big funds are accumulating CRISPR Therapeutics AG (1CG) stockPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
Applying Wyckoff theory to CRISPR Therapeutics AG stockCPI Data & Stock Market Timing Techniques - newser.com
How to build a dashboard for CRISPR Therapeutics AG stock2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
Is CRISPR Therapeutics AG stock a buy for dividend growthJuly 2025 Rallies & Low Drawdown Investment Strategies - newser.com
CRISPR Therapeutics AG stock trendline breakdownJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Is CRISPR Therapeutics AG stock a top pick in earnings seasonJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway - GuruFocus
Gene editing therapy companies rise on word of streamlined FDA approval process - Seeking Alpha
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP - GuruFocus
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com
Key metrics from CRISPR Therapeutics AG’s quarterly dataWeekly Trend Report & AI Forecasted Stock Moves - newser.com
Visual analytics tools that track CRISPR Therapeutics AG performanceQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
Key resistance and support levels for CRISPR Therapeutics AGJuly 2025 Macro Moves & Low Risk Entry Point Guides - newser.com
Visualizing CRISPR Therapeutics AG stock with heatmapsEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Can CRISPR Therapeutics AG (1CG) stock double in coming years2025 Market WrapUp & Safe Capital Preservation Plans - newser.com
Building trade automation scripts for CRISPR Therapeutics AG2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Can you recover from losses in CRISPR Therapeutics AG2025 Risk Factors & Technical Buy Zone Confirmations - newser.com
Analyzing net buyer seller activity in CRISPR Therapeutics AGQuarterly Portfolio Review & High Return Trade Guides - newser.com
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):